DB:MFY

Stock Analysis Report

Executive Summary

Mochida Pharmaceutical Co., Ltd. produces and sells pharmaceuticals, skincare products, and diagnostics solutions in Japan.

Snowflake

Fundamentals

Flawless balance sheet and undervalued.

Share Price & News

How has Mochida Pharmaceutical's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.6%

MFY

0.5%

DE Pharmaceuticals

2.4%

DE Market


1 Year Return

-2.3%

MFY

-3.8%

DE Pharmaceuticals

4.9%

DE Market

Return vs Industry: MFY exceeded the German Pharmaceuticals industry which returned -3.8% over the past year.

Return vs Market: MFY underperformed the German Market which returned 4.9% over the past year.


Shareholder returns

MFYIndustryMarket
7 Day-0.6%0.5%2.4%
30 Day-4.1%-1.1%2.3%
90 Day-12.1%8.2%2.7%
1 Year-0.9%-2.3%-0.5%-3.8%8.2%4.9%
3 Year-0.3%-5.8%30.4%15.8%18.3%8.0%
5 Year60.6%46.3%30.8%9.1%44.2%24.6%

Price Volatility Vs. Market

How volatile is Mochida Pharmaceutical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Mochida Pharmaceutical undervalued compared to its fair value and its price relative to the market?

37.8%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: MFY (€33) is trading below our estimate of fair value (€53.06)

Significantly Below Fair Value: MFY is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: MFY is good value based on its PE Ratio (13.7x) compared to the Pharmaceuticals industry average (22.5x).

PE vs Market: MFY is good value based on its PE Ratio (13.7x) compared to the German market (19.2x).


Price to Earnings Growth Ratio

PEG Ratio: MFY is good value based on its PEG Ratio (0.8x)


Price to Book Ratio

PB vs Industry: MFY is good value based on its PB Ratio (1.3x) compared to the DE Pharmaceuticals industry average (2x).


Next Steps

Future Growth

How is Mochida Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

17.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MFY's forecast earnings growth (17.9% per year) is above the savings rate (0.2%).

Earnings vs Market: MFY's earnings (17.9% per year) are forecast to grow faster than the German market (12.8% per year).

High Growth Earnings: MFY's earnings are forecast to grow, but not significantly.

Revenue vs Market: MFY's revenue (1% per year) is forecast to grow slower than the German market (5% per year).

High Growth Revenue: MFY's revenue (1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MFY's Return on Equity is forecast to be low in 3 years time (6.3%).


Next Steps

Past Performance

How has Mochida Pharmaceutical performed over the past 5 years?

-0.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: MFY's earnings have declined by -0.1% per year over the past 5 years.

Accelerating Growth: MFY's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: MFY had negative earnings growth (-44.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (1.9%).


Return on Equity

High ROE: MFY's Return on Equity (4.7%) is considered low.


Return on Assets

ROA vs Industry: MFY's Return on Assets is below or equal to the Pharmaceuticals industry average last year.


Return on Capital Employed

ROCE Improving: MFY's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is Mochida Pharmaceutical's financial position?


Financial Position Analysis

Short Term Liabilities: MFY's short term assets (¥116.0B) exceeds its short term liabilities (¥27.2B)

Long Term Liabilities: MFY's short term assets (116.0B) exceeds its long term liabilities (5.4B)


Debt to Equity History and Analysis

Debt Level: MFY is debt free.

Reducing Debt: MFY has no debt compared to 5 years ago when its debt to equity ratio was 0.9%.

Debt Coverage: MFY has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: MFY has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: MFY has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if MFY's debt is covered by short term assets.


Next Steps

Dividend

What is Mochida Pharmaceutical's current dividend yield, its reliability and sustainability?

1.95%

Current Dividend Yield


Dividend Yield vs Market

company2.0%marketbottom25%1.5%markettop25%3.8%industryaverage3.0%forecastin3Years2.0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: MFY's dividend (1.95%) is higher than the bottom 25% of dividend payers in the German market (1.46%).

High Dividend: MFY's dividend (1.95%) is low compared to the top 25% of dividend payers in the German market (3.79%).

Stable Dividend: MFY's dividend payments have been volatile in the past 10 years.

Growing Dividend: MFY's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (29.6%), MFY's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

What is the CEO of Mochida Pharmaceutical's salary, the management and board of directors tenure and is there insider trading?


CEO

Naoyuki Mochida 0

20.8yrs

Tenure

0

Mr. Naoyuki Mochida has been the President of Mochida Pharmaceutical Co. Ltd since 1999 and serves as its Director. 


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Naoyuki Mochida

    President & Director

    • Tenure: 20.8yrs
  • Yoichi Kono

    Executive MD & Director

    • Tenure: 0yrs
  • Keiichi Sagisaka

    Senior Executive MD & Director

    • Tenure: 0yrs
  • Takayuki Kato

    Executive Officer

    • Tenure: 0yrs
  • Chu Sakata

    Senior Executive MD & Director

    • Tenure: 0yrs
  • Kiyoshi Mizuguchi

    Executive MD & Director

    • Tenure: 0yrs
  • Junichi Sakaki

    Executive MD & Director

    • Tenure: 0yrs
  • Kazumasa Fukuchi

    Executive Officer

    • Tenure: 0yrs
  • Yutaka Kawakami

    Executive Director

    • Tenure: 0yrs
  • Yoshiharu Hashimoto

    Executive Director

    • Tenure: 0yrs

Board Members

  • Naoyuki Mochida

    President & Director

    • Tenure: 20.8yrs
  • Yoichi Kono

    Executive MD & Director

    • Tenure: 0yrs
  • Keiichi Sagisaka

    Senior Executive MD & Director

    • Tenure: 0yrs
  • Chu Sakata

    Senior Executive MD & Director

    • Tenure: 0yrs
  • Tomoo Kugisawa

    Outside Director

    • Tenure: 0yrs
  • Kiyoshi Mizuguchi

    Executive MD & Director

    • Tenure: 0yrs
  • Junichi Sakaki

    Executive MD & Director

    • Tenure: 0yrs
  • Hirokuni Sogawa

    Outside Director

    • Tenure: 0yrs
  • Yutaka Kawakami

    Executive Director

    • Tenure: 0yrs
  • Yoshiharu Hashimoto

    Executive Director

    • Tenure: 0yrs

Company Information

Mochida Pharmaceutical Co., Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Mochida Pharmaceutical Co., Ltd.
  • Ticker: MFY
  • Exchange: DB
  • Founded: 1913
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: JP¥160.644b
  • Listing Market Cap: JP¥1.329b
  • Shares outstanding: 39.23m
  • Website: https://www.mochida.co.jp

Number of Employees


Location

  • Mochida Pharmaceutical Co., Ltd.
  • 7, Yotsuya 1-chome
  • Shinjuku-ku
  • Tokyo
  • 160-8515
  • Japan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
4534TSE (The Tokyo Stock Exchange)YesCommon StockJPJPYJan 1992
MFYDB (Deutsche Boerse AG)YesCommon StockDEEURJan 1992

Biography

Mochida Pharmaceutical Co., Ltd. produces and sells pharmaceuticals, skincare products, and diagnostics solutions in Japan. It provides cardiovascular, analgesic, gastrointestinal, neurological, anti-infec ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/21 20:46
End of Day Share Price2019/10/21 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.